Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize data concerning the cardiovascular, renal, metabolic, and neurologic complications associated with HIV and antiretroviral therapy
- Discuss issues regarding the management of patients with HIV and coinfected with hepatitis B virus, human papillomavirus, or tuberculosis
- Describe complications specific to certain HIV-infected populations such as women and men who have sex with men
- Explain the efficacy and safety results associated with the use of abacavir/lamivudine vs tenofovir/emtricitabine in treatment-naive patients.
Topics covered include:
- Association Between Abacavir Use and Risk for Cardiovascular Events
- No Effect on Lipohypertrophy With Switch From Boosted PI to Boosted Atazanavir
- Improvement in Limb Fat With a Switch From Zidovudine/Lamivudine to Emtricitabine/Tenofovir
- Risk Factors for Nevirapine Toxicity
- Relationship Between Tenofovir and Renal Dysfunction
- Low Bone Mineral Density Among HIV-Uninfected Men Who Have Sex With Men
- Limitations of Transient Elastography for Liver Fibrosis Determination
- Occult HBV Infection in the Setting of HIV Infection
- Pregabalin for Treatment of Peripheral Neuropathy
- Health-Related Issues in HIV-Infected Women
- Relationships Between Tuberculosis and HAART
- Concluding Remarks